Multivariate analyses of axi-cel safety outcomes by V2Vt. Multivariate analyses of CRS (any-grade or grade ≥3), ICANS (any-grade or grade ≥3), prolonged neutropenia, and prolonged thrombocytopenia in patients treated with axi-cel. Patients were from the CIBMTR registry PASS cohort. CRS and ICANS were evaluated based on events reported on the 100-day follow-up case-report form, and prolonged neutropenia and thrombocytopenia were evaluated among patients alive at day 30 after infusion. Covariates for stepwise selection and multivariable adjustment were age, sex, race, ethnicity, ECOG PS before infusion, comorbidities (pulmonary, cardiac/cerebrovascular/heart valve disease, hepatic, and renal), histologic transformation, disease characteristics at initial diagnosis (double/triple hit, disease stage, elevated LDH and >1 extranodal involvement), chemosensitivity before infusion, number of prior lines of therapy, prior HCT, year of infusion, time from initial diagnosis to infusion, and use of bridging therapy.